12:00 AM
 | 
Nov 18, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Radium-223 regulatory update

The European Commission approved an MAA from Bayer for Xofigo radium-223 dichloride to treat adults with castration-resistant prostate cancer (CRPC), symptomatic bone metastases and no known visceral metastases. The...

Read the full 124 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >